2022
1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS)
Yan L, Henegar C, Gordon K, Hicks C, Vannappagari V, Justice A, Aslan M. 1265. Effectiveness and Durability of Dolutegravir (DTG)-Based Regimens in Older People Living with HIV (PLWH) from the Veterans Aging Cohort Study (VACS). Open Forum Infectious Diseases 2022, 9: ofac492.1096. PMCID: PMC9752102, DOI: 10.1093/ofid/ofac492.1096.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyDTG-based regimensAging Cohort StudyViiV HealthcareCohort studyOlder peopleART-experienced individualsCD4 cell countEnd of studyRegimen discontinuationRegimen initiationAntiretroviral regimensVirologic failureART-naïveMultiple comorbiditiesHIV managementOlder PLWHPLWHTreatment responseTreatment statusRegimensTreatment experienceDolutegravirRaltegravirCell count
2021
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
Wyse JJ, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, Fiellin DA, Moore BA, Korthuis PT, Kennedy AJ, Oldfield BJ, Gaither JR, Gordon KS, Skanderson M, Barry DT, Bryant K, Crystal S, Justice AC, Kraemer KL. Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV. AIDS And Behavior 2021, 26: 975-985. PMID: 34495424, PMCID: PMC8840957, DOI: 10.1007/s10461-021-03452-0.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderVeterans Aging Cohort StudyHIV statusUse disordersOpioid agonist treatmentAging Cohort StudyDiagnosis of HCVTwelve-month retentionPositive health outcomesOAT retentionAgonist therapyCohort studyHIV managementAgonist treatmentPredictors of retentionPatientsHealth outcomesHistory of homelessnessHIVLower likelihoodImproved likelihoodLikelihood of initiationBuprenorphineDisorders